Headlines
- Why Immunotherapy Stocks Could Be Set for a Big Moveat Motley Fool(Fri May 24)
- Commit To Buy Dendreon At $2, Earn 26.5%at TheStreet(Thu May 23)
- Biotech Investing for Beginnersat Motley Fool(Wed May 22)
- Dendreon Analysts Getting Very Skepticalat Seeking Alpha(Wed May 22)
- Bayer's Xofigo Cleared in the USZacks(Thu May 16)
- One Person's Trash Is Another Person's Treasure Portfolioat Motley Fool(Thu May 16)
- DENDREON CORP FinancialsEDGAR Online Financials(Wed May 15)
- Bayer, Algeta Win U.S. Approval for Prostate Cancer Drugat Bloomberg(Wed May 15)
- Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha(Wed May 15)
- Dendreon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)at Seeking Alpha(Tue May 14)
- Once Heralded Dendreon May Be Approaching The End Of Its Financial Roadat Seeking Alpha(Tue May 14)
- Does Dendreon Still Have Potential?at Wall St. Cheat Sheet(Tue May 14)
- Three of WellPoint's directors resign for personal reasonsat Reuters(Mon May 13)
- 2 Scenarios Where Buy and Hold Rarely Worksat Motley Fool(Mon May 13)
- Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbertat Seeking Alpha(Mon May 13)
Press Releases
- StockCall Pre-Market Review on DNDN, SRPT, ACAD, CTIC, and MDVNAccesswire(Wed May 8)
- How Cancer Beats the Immune SystemAccesswire(Thu Mar 7)
Must Read
- Closed business in Corner Brook an eyesore, says board of tradeCBC(Sat 5:56AM EDT)
- News Corp. board approves poison pill, $500 million stock buyback before splitThe Canadian Press(Fri May 24)
- National Bank considering new acquisitions in Canadian wealth managementThe Canadian Press(Fri May 24)
- MTS to sell Allstream to Egyptian investment group, focus on Manitoba marketThe Canadian Press(Fri May 24)
- Loonie lower despite positive durable goods data, little else on calendarThe Canadian Press(Fri May 24)
